September 18, 2008

Honorable Nancy Pelosi Speaker U.S. House of Representatives H-232 U.S. Capitol Building Washington, DC 20515

Honorable John A. Boehner Minority Leader U.S. House of Representatives H-204 U.S. Capitol Building Washington, DC 20515

Dear Speaker Pelosi and Minority Leader Boehner:

As members of the health advocacy community, we urge you to reauthorize the Small Business Innovation Research (SBIR) program before the close of the 110<sup>th</sup> Congress with the restoration of majority venture capital-backed companies' eligibility to compete for these grants. The SBIR program is a set-aside of federal research and development grant monies that are reserved for innovative, small business applicants. These funds provide critical "seed" money for early stage research and development being undertaken by small companies with fewer than 500 employees.

After twenty years of participating in the program, the Small Business Administration (SBA) ruled in 2003 that small companies that are majority venture capital-backed could no longer apply for grants regardless of how few employees the companies have. Because of the unique capital needs of small biotechnology companies, most are now ineligible to compete for these grants. As a result of SBA's reinterpretation, the SBIR applicant pool is shrinking at the National Institutes of Health (NIH). In addition, without SBIR program support, other sources of funding for this kind of cutting-edge, patient-oriented research are difficult, if not impossible, to obtain. As NIH Director Dr. Elias Zerhouni stated in a letter to the SBA, "NIH must turn away many deserving applicants, and the goals of the SBIR program are being undermined."

The current eligibility guidelines are prohibiting many of the most innovative companies from competing for crucial early stage research and development funding. These limitations negatively impact Americans living with rare diseases, diabetes, Parkinson's, lupus and leukemia, among other diseases, who ultimately need better treatments and cures. From a patient perspective it does not seem logical, and is in fact scary, that we eliminate from eligibility research projects that otherwise merit funding, because of the financial structure of the company. These companies need both federal grants and

venture capital to support the high cost of biomedical research. To eliminate the very ones that are strong enough to attract private money doesn't penalize companies, it penalizes patients. We respectfully urge you to restore SBIR eligibility for majority venture-backed companies.

We applaud your efforts to reauthorize and enhance SBIR grants by making them more competitive and responsive to research opportunities. We strongly urge you to do everything in your power to ensure passage of this legislation in the coming weeks, before the close of the 110<sup>th</sup> Congress.

## Sincerely,

**AIDS Institute** 

Alliance for Aging Research

Alpha-1 Association

Alpha-1 Foundation

Alzheimer's Drug Discovery Foundation

American Association of Neurological Surgeons

American Autoimmune Related Diseases Association

American Gastroenterological Association

American Osteopathic Association

American Society of Nephrology

American Tinnitus Association

APBD Research Foundation

Association for Research in Vision and Ophthalmology

Association of American Medical Colleges

Autism Society of America

C3: Colorectal Cancer Coalition

Candlelighters Childhood Cancer Foundation

Children's Tumor Foundation

Christopher and Dana Reeve Foundation

Coalition of Heritable Disorders of Connective Tissue

Community Health Charities of America

Congress of Neurological Surgeons

**COPD** Foundation

Cutaneous Lymphoma Foundation

Cystic Fibrosis Foundation

**Easter Seals** 

**Epilepsy Therapy Project** 

**FasterCures** 

Foundation Fighting Blindness

Foundation for Sarcoidosis Research

Genetic Alliance

Genetic Alliance BioBank

Hemophelia Federation of America

Huntington's Disease Society of America

Hydrocephalus Association

Infectious Diseases Society of America

International Cancer Advocacy Network

Kidney Cancer Association

Men's Health Network

Michael J. Fox Foundation for Parkinson's Research

Multiple Myeloma Research Foundation

Muscular Dystrophy Association

National Alliance Mental Illness

National Alopecia Areata Foundation

National Health Council

National Hispanic Medical Association

National Indian Health Board

National Multiple Sclerosis Society

National Psoriasis Foundation

New York Stem Cell Foundation

Parkinson's Action Network

**PXE** International

Research! America

RetireSafe

Society for Women's Health Research

Sturge-Weber Foundation

TII CANN - Title II Community AIDS National Network

Vietnam Veterans of America

ZERO - The Project to End Prostate Cancer